CATALOGO DEI PRODOTTI DELLA RICERCA

FRACASSO, Giulio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.595
EU - Europa 5.636
AS - Asia 4.492
SA - Sud America 583
Continente sconosciuto - Info sul continente non disponibili 122
AF - Africa 109
OC - Oceania 8
Totale 17.545
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.415
RU - Federazione Russa 2.030
SG - Singapore 1.768
CN - Cina 1.303
GB - Regno Unito 1.279
IT - Italia 533
BR - Brasile 472
VN - Vietnam 432
HK - Hong Kong 378
FR - Francia 323
SE - Svezia 322
IE - Irlanda 296
DE - Germania 278
FI - Finlandia 240
KR - Corea 151
CA - Canada 101
UA - Ucraina 83
IN - India 79
TR - Turchia 58
BD - Bangladesh 56
JP - Giappone 54
MX - Messico 48
NL - Olanda 46
AR - Argentina 44
PL - Polonia 38
ID - Indonesia 35
ES - Italia 32
IQ - Iraq 30
BE - Belgio 29
NG - Nigeria 26
ZA - Sudafrica 26
IR - Iran 23
PK - Pakistan 20
EC - Ecuador 16
SA - Arabia Saudita 14
AT - Austria 12
CH - Svizzera 11
LT - Lituania 11
MA - Marocco 11
PH - Filippine 11
UZ - Uzbekistan 11
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
CO - Colombia 10
GR - Grecia 9
UY - Uruguay 9
EG - Egitto 8
BY - Bielorussia 7
CL - Cile 7
HR - Croazia 7
JM - Giamaica 7
JO - Giordania 7
PE - Perù 7
PT - Portogallo 7
AU - Australia 6
AZ - Azerbaigian 6
MY - Malesia 6
PY - Paraguay 6
TN - Tunisia 6
AL - Albania 5
DZ - Algeria 5
KE - Kenya 5
RO - Romania 5
TW - Taiwan 5
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
KW - Kuwait 4
LV - Lettonia 4
NP - Nepal 4
PA - Panama 4
BJ - Benin 3
CZ - Repubblica Ceca 3
EU - Europa 3
HN - Honduras 3
IL - Israele 3
KZ - Kazakistan 3
LU - Lussemburgo 3
OM - Oman 3
SN - Senegal 3
TG - Togo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
CM - Camerun 2
CY - Cipro 2
GT - Guatemala 2
KG - Kirghizistan 2
MD - Moldavia 2
NO - Norvegia 2
PR - Porto Rico 2
QA - Qatar 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
Totale 17.404
Salva come PNG Salva come JPEG
Città #
Southend 1.073
Singapore 930
Moscow 701
Ashburn 660
Chandler 644
Dallas 630
Jacksonville 565
San Jose 547
Woodbridge 408
Hong Kong 363
Dublin 293
Ann Arbor 281
Verona 260
Beijing 247
Council Bluffs 225
Houston 208
The Dalles 177
Ho Chi Minh City 135
New York 113
Lawrence 106
Princeton 106
Wilmington 100
Los Angeles 96
Jinan 92
Hanoi 84
Nanjing 80
Buffalo 65
Shenyang 65
Tianjin 64
Helsinki 63
Santa Clara 58
Tokyo 50
Hebei 49
São Paulo 48
Changsha 43
Columbus 42
Munich 41
Sindelfingen 39
Seoul 37
Zhengzhou 37
Dong Ket 35
Orem 35
Milan 34
Chennai 33
London 33
Montreal 32
Seattle 32
Boardman 31
Warsaw 30
Brussels 29
Redondo Beach 29
Guangzhou 28
Jakarta 27
Denver 26
Haikou 25
Ningbo 25
Hangzhou 24
Jiaxing 24
Abuja 23
Redwood City 23
San Francisco 23
Atlanta 22
Frankfurt am Main 22
Taizhou 22
Johannesburg 21
Taiyuan 21
Brooklyn 20
Stockholm 20
Turku 20
Da Nang 19
Nanchang 19
Amsterdam 18
Norwalk 18
Bologna 17
Boston 17
Chicago 17
Lancaster 17
Paris 17
Fuzhou 16
Rio de Janeiro 15
Rome 15
Toronto 15
Redmond 14
Falkenstein 13
Manchester 13
Montréal 13
Padova 13
Shanghai 13
Mexico City 12
Nuremberg 12
Poplar 12
Tashkent 11
Barnet 10
Biên Hòa 10
Haiphong 10
Phoenix 10
Belo Horizonte 9
Brasília 9
Curitiba 9
Lappeenranta 9
Totale 11.016
Salva come PNG Salva come JPEG
Nome #
Anti PSMA immunotoxins activity against prostate cancer cell lines. 293
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 274
Immunotoxins and other conjugates: preparation and general characteristics. 262
Anti-PSMA-Immunotoxins: a new therapeutical strategy for selective targeting of toxins to prostate cancer cells. 252
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 242
Filamin A-mediated interaction of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin regulates survival of advanced prostate cancer cells 240
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 238
A SERRS/MRI multimodal contrast agent based on naked Au nanoparticles functionalized with a Gd(iii) loaded PEG polymer for tumor imaging and localized hyperthermia 232
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 231
Reductive activation of ricin and ricin-A chain immunotoxins by Protein Disulfide Isomerase and Thioredoxin Reductase system. 221
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 220
Cooperation of Prostate Specific Membrane Antigen with beta 1 integrin promotes the survival of aggressive prostate cancer cells 218
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 216
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 215
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 213
Characterization of In-111-labeled site-specifically conjugated anti-PSMA antibody-drug conjugates for treatment of PSMA-expressing tumors 212
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 211
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 210
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 208
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin 204
Biodistribution of In-111-labeled D2B IgG, F(ab’)2 and Fab fragments in nude mice bearing human prostate cancer xenografts 199
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 197
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 196
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 196
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 193
Targeted Killing of Prostate Cancer Cells using Antibody-Drug conjugated Carbon Nanohorns 193
Protein Disulfide Isomerase and Thioredoxin Reductase: a ricin disulfide reducing system in the endoplasmic reticulum. 187
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 186
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 186
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 186
Acute sarcomeric M-Line Disease associated with ATP synthase subunit α autoantibodies in ankylosing spondylitis 184
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors 183
Top-down synthesis of multifunctional iron oxide nanoparticles for macrophage labelling and manipulation 182
Characterization of an In-111-labeled anti-PSMA antibody-photosensitizer conjugate for targeted photodynamic therapy of PSMA-expressing tumors 181
N-terminal deletion affetcs catalytic activity of saporin toxin. 180
Cloning and characterisation of canine prostate-specific membrane antigen 180
Discriminatory role of detergent-resistant membranes in the dimerization and endocytosis of prostate-specific membrane antigen 180
The Filamin A-mediated cooperation of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin promotes the survival of aggressive prostate cancer cells. 180
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 179
Plasmonic Nanostructures for SERRS Multiplexed Identification of Tumor-Associated Antigens 178
Targeted delivery of photosensitizers: efficacy and selectivity issues revealed by multifunctional ORMOSIL nanovectors in cellular systems 178
Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. 176
Prostate-specific membrane antigen associates already in the endoplasmic reticulum with lipid microdomains 175
Prostate Specific Membrane Antigen (PSMA) associates with Filamin A, beta1 integrin, pp130CAS and pSrc thus regulating the activation of beta1 integrin and the survival of prostate cancer cells. 175
An electrochemiluminescent-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer. 175
Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells. 173
Highly sensitive electrochemiluminescence detection of a prostate cancer biomarker 171
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy 169
Magneto-Plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging 167
Pegylated silica nanoparticles: cytotoxicity and macrophage uptake 167
Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures 167
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer 165
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 162
Identification of Ricin A chain HLA II-restricted epitopes by human T-cell clones. 159
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) 159
SERS IMAGING OF CANCER CELLS WITH ANTIBODY FUNCTIONALIZED GOLD NANOPARTICLES 158
Prostate-specific membrane antigen (PSMA) associates early in the endoplasmic reticulum with lipid microdomains 157
Expression of myelin basic protein (MBP) epitopes in human non-neural cells revealed by two anti-MBP IgM monoclonal antibodies 154
Targeted Silica Nanoparticles for PhotoDynamic Therapy (PDT) 153
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extendash}Part I 150
Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection 149
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin 146
Polymer-coated silver-iron nanoparticles as efficient and biodegradable MRI contrast agents 146
SERS labels for quantitative assays: application to the quantification of gold nanoparticles uptaken by macrophage cells 143
Gangliosides act as onconeural antigens in paraneoplastic neuropathies. 141
Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones 140
Targeting human prostate cancer with (111) In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. 137
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 135
Laser generated gold nanocorals with broadband plasmon absorption for photothermal applications 132
Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy 131
Safe Core-Satellite Magneto-Plasmonic Nanostructures for Efficient Targeting and Photothermal Treatment of Tumor Cells 130
SERRS Multiplexing with Multivalent Nanostructures for the Identification and Enumeration of Epithelial and Mesenchymal Cells 130
Simple and Rapid Non-Enzymatic Procedure Allows the Isolation of Structurally Preserved Connective Tissue Micro-Fragments Enriched with SVF 129
In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe 128
Pharmacokinetics of intrathecal transferrin-ricin A chain immunotoxins 127
Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells 127
Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model 127
Effect of therapeutic macromolecules in spheroids 126
The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity 126
Mitoxantrone-loaded nanoferritin slows tumor growth and improves the overall survival rate in a subcutaneous pancreatic cancer mouse model 125
Improved method for carbohydrate-deficient transferrin determination in human serum by capillary zone electrophoresis 124
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 123
Genetic grafting of membrane-acting peptides to the cytotoxin dianthin augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin-toxin conjugates. 123
Prostate-specific membrane antigen routing to the cell surface implicates an early association step in the endoplasmic reticulum with lipid microdomains. 120
Ribosome-inactivating protein-containing conjugates for therapeutic use 120
G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children 117
Efficient AuFeOx Nanoclusters of Laser-Ablated Nanoparticles in Water for Cells Guiding and Surface-Enhanced Resonance Raman Scattering Imaging 116
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen 114
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extemdash}Part {II}. Toxicity, Pharmacokinetics and Biodistribution 114
Immunology of RIPs and their Immunotoxins, in Ribosome-inactivating Proteins: Ricin and Related Proteins 113
Dual modality imaging of PSMA-expressing prostate cancer with a new radiolabeled anti-PSMA monoclonal antibody conjugated with IRDye800CW 112
PSMA as a new target for anti-vascular therapy. Development of an in vitro model of PSMA positive endothelial cells. 110
Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness 109
New Tc-99m-radioimmunoconjugates for pancreatic carcinoma detection 106
Targeting prostate cancer cells with D2B-gold Nanoparticles 105
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma 104
Different Glycoforms of Prostate-Specific Membrane Antigen are intracellularly transported through their Association with Distinct Detergent-Resistant Membranes 103
Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements 102
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging 102
Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors 102
Totale 16.562
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.371
article - articoli 43.027
book - libri 0
conference - conferenze 13.408
curatela - curatele 0
other - altro 0
patent - brevetti 1.029
selected - selezionate 0
volume - volumi 907
Totale 116.742
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022805 0 250 14 81 37 18 16 51 20 33 74 211
2022/20231.892 147 181 171 322 136 457 74 130 200 13 46 15
2023/2024898 43 85 91 94 109 122 35 55 12 79 123 50
2024/20252.436 113 153 61 367 169 82 123 112 403 186 223 444
2025/20267.234 506 447 618 1.103 1.808 498 723 345 508 408 102 168
2026/2027233 104 129 0 0 0 0 0 0 0 0 0 0
Totale 17.545